D
espite the best efforts of both the physician and the patient, a certain proportion of patients with Crohn's disease (CD) will inevitably need to undergo an operation for the management of their disease. The literature suggests that approximately 75% of patients with CD will require at least one resection in their lifetime (1) . Surgical resection is a pivotal event in the patient's disease because it potentially marks an occasion to 'reset the clock' to the time where none or a very minimal amount of the inflammation is present in the area of the patient's small bowel or colon, which was previously affected with CD. Therefore, after recovering from the operation, most patients feel the healthiest they have felt in a long time. Due to this fact, and because the gastroenterologist may have taken a more distant role in the management of the patient because the surgeon has become more involved, this event may unfortunately lead to a parting of ways between the gastroenterologist and the patient, which would be appropriate if the operation was a cure for CD. Unfortunately, no such cure exists. Three years after surgical resection, 85% of all patients will have signs suggestive of recurrent CD (2) . Furthermore, within 15 years, more than 70% of patients will require a second operation (1) . This predicted high recurrence rate, along with other ongoing issues relating to patients with CD, emphasizes the importance of maintaining a close follow-up of these patients.
Because of the progressive nature of this condition, different prophylactic medications have been studied to prevent recurrence of CD (3). Unfortunately, none of the medications studied have shown suitable clinical efficacy and tolerability; therefore, a current recommended therapy for prevention of postoperative recurrence of CD is lacking. Due to this void in our treatment regimen for CD, identifying those patients who are most likely to have recurring disease and offering them prophylactic treatment is an important strategy. Many studies have focused on finding predictors of recurrent disease. Patient characteristics (ie, smoking [4] [5] [6] and perianal disease [7] ), surgical techniques (stapled anastamosis [8] ) and histological characteristics (granulomas [9] and myenteric plexitis [10] ) have all been suggested to identify those patients most likely to have recurrence of the disease. However, the quality of many of these studies limits the reliability of these findings, and studies have also shown that many of these factors do not predict recurrent disease.
Endoscopic evidence of recurrent CD has been shown to predict clinically symptomatic CD (2) . In a prospective cohort study (2), 89 patients who had ileal resections between 1979 and 1984 were followed to evaluate the natural history of early postoperative endoscopic lesions. Eighty-two of these patients received a colonoscopy with examination of the neoterminal ileum within one year after surgery. At ileocolonoscopy, ileal lesions were scored as followed: I0 -no lesions, I1 -fewer than five aphthous lesions, I2 -more than five aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions confined to the ileocolonic anastamosis (less than 1 cm in length), I3 -diffuse aphthous ileitis with diffusely inflamed mucosa and I4 -diffuse inflammation with already large ulcers, nodules and/or narrowing. Seventy-three per cent of these patients had endoscopic evidence of recurrent disease within one year of surgery, but only 20% of these patients had recurrent symptoms. Three years after surgery, the endoscopic recurrence rate was 83% and the symptomatic recurrence rate was 34%. Various clinical characteristics were analyzed in this study, and the best predictor of symptomatic recurrence of CD was endoscopic recurrence. There was a significant correlation between the extent of recurrent disease, as assessed by this endoscopic scoring system, and the chance of symptomatic recurrence. There was a strong, statistically significant increased risk of developing symptomatic recurrent CD if the patient had I4 or I3 lesions compared with either I0 or I1 lesions (P=0.0001 for both comparisons).
This study provided very important information relating to how patients with CD should be followed postsurgical resection. First, the results have proved that the vast majority of patients will have endoscopic recurrence of CD within three years following surgical resection. Although previously appreciated, the fact that only 34% of patients had symptomatic recurrent disease demonstrates that endoscopic evidence of active disease does not necessarily correlate with patient symptoms. However, the assessment used in this trial of recurrent disease has not been validated. In fact, the assessment of clinical recurrence after surgical resection of CD varies among many of the different therapeutic trials examining treatment for medical prophylaxis of CD postsurgical resection; this discrepancy must be addressed in future trials evaluating this patient population. Regardless of this limitation, endoscopic recurrence is clearly an important predictor of clinical recurrent CD.
Colonoscopy with careful examination of the neoterminal ileum is an important diagnostic tool that I use in following
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Current endoscopic practices patients with CD after surgical resection. I recommend that all patients be considered for a colonoscopy six months to one year after their surgery. Following this colonoscopy, I consider additional colonoscopy surveillance based on the endoscopic findings and the patient's previous clinical course of disease before their resection. As previously mentioned, because the data on postoperative prophylaxis medical treatment for CD does not suggest a particularly effective and tolerable strategy, every patient should not be placed on medical therapy after their resection. However, ileocolonic examination for the purpose of evaluating the presence of recurrent CD addresses two important considerations. First, those with evidence of severe recurrent disease (I3 or I4 lesions) are patients more likely to have clinical recurrent disease. Therefore, these patients would most likely benefit from treatment (such as azathioprine) before experiencing symptoms. Second, documenting mucosal disease to those patients in whom one would consider starting prophylactic treatment is important, particularly when the decision is to introduce immunosuppressive therapy. Compliance in this group of patients is a particular challenge; in many instances these patients feel better than they have for a long period of time because before their operation they were failing medical therapy. This current way of practice has not been evaluated in a controlled trial setting. Proper clinical trials evaluating this strategy are required to determine if the medications that have been suggested to be effective in the prevention of recurrence would work in this cohort of patients, and at what degree of endoscopic recurrence is it appropriate to intervene. Other more sensitive methods for evaluating the small bowel (ie, capsule studies) may theoretically lead to improved compliance; however, they have not been studied extensively in the postoperative arena. Although resources in many areas for endoscopic examinations are limited, the aggressive treatment of specific patients with CD may have a positive benefit on subsequent resource utilization if symptomatic relapses can be prevented.
A final role of colonoscopy which should not be overlooked in this patient group, is in those individuals who previously had both small bowel and significant colonic involvement (more than one-third of their colon affected based on endoscopic examination) before their resection. Provided the portion of the colon with previous evidence of active CD remains, they require typical endoscopic dysplasia surveillance after they had had their disease for at least 10 years. The appropriate way to perform endoscopic dysplasia surveillance has been previously reviewed (11) .
As we continue to improve our understanding regarding the etiology of CD, our therapy for CD improves. These accomplishments have allowed investigators to begin to use mucosal healing as an achievable end point in clinical studies. Although mucosal healing as a guide to treatment response is not yet ready to be used in clinical practice, the evaluation of mucosal disease in patients with CD who have had a surgical resection should be considered. This method of following this particular cohort of patients may interrupt the progressive disease course of patients with CD who require surgical resection for therapy by introducing possibly effective medical prophylaxis. Furthermore, this method may limit the exposure of medical therapy to patients with no endoscopic evidence of recurrence in whom the benefit for treatment maybe minimal, and they would be spared potential toxicity from these medications.
